Human recombinant erythropoietin significantly improves tumor oxygenation independent of its effects on hemoglobin

Cancer Research

Volumn 63, Issue 19, 2003, Pages 6162-6165

  Blackwell, Kimberly L ^a,c   Kirkpatrick, John P ^a   Snyder, Stacey A ^a   Broadwater, Gloria ^a   Farrell, Francis ^b   Jolliffe, Linda ^b   Brizel, David M ^a   Dewhirst, Mark W ^a  

^a DUKE CANCER INSTITUTE   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEMATOCRIT; HEMOGLOBIN DETERMINATION; HYPOXIA; NONHUMAN; OXIMETRY; PRIORITY JOURNAL; RAT; TISSUE OXYGENATION; TUMOR; TUMOR VOLUME;

ADENOCARCINOMA; ANIMALS; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMOGLOBINS; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; NEOPLASM TRANSPLANTATION; OXYGEN; PARTIAL PRESSURE; RANDOM ALLOCATION; RATS; RATS, INBRED F344;

EID: 0141988695     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Brown, J. M., and Giaccia, A. J. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res., 58: 1408-1416, 1998.
2. Sutherland, R. M. Tumor hypoxia and gene expression-implications for malignant progression and therapy. Acta Oncol., 37: 567-574, 1998.
3. Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., and Giaccia, A. J. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature (Lond.), 379: 88-91, 1996.
4. Harris, A. L. Hypoxia - a key regulatory factor in tumour growth. Nat. Rev. Cancer, 2: 38-47, 2002.
5. Hockel, M., Schlenger, K., Hockel, S., Aral, B., Schaffer, U., and Vaupel, P. Tumor hypoxia in pelvic recurrences of cervical cancer. Int. J. Cancer, 79: 365-369, 1998.
6. Rofstad, E. K., Sundfor, K., Lyng, H., and Trope, C. G. Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis. Br. J. Cancer, 83: 354-359, 2000.
7. Sundfor, K., Lyng, H., and Rofstad, E. K. Tumour hypoxia and vascular density as predictors of metastasis in squamous cell carcinoma of the uterine cervix. Br. J. Cancer, 78: 822-827, 1998.
8. Hockel, M., Schlenger, K., Aral, B., Mitze, M., Schaffer, U., and Vaupel, P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res., 56: 4509-4515, 1996.
9. Fyles, A. W., Milosevic, M., Wong, R., Kavanagh, M. C., Pintilie, M., Sun, A., Chapman, W., Levin, W., Manchul, L., Keane, T. J., and Hill, R. P. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother. Oncol., 48: 149-156, 1998.
10. Fyles, A., Milosevic, M., Hedley, D., Pintilie, M., Levin, W., Manchul, L., and Hill, R. P. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J. Clin. Oncol., 20: 680-687, 2002.
11. Haensgen, G., Krause, U., Becker, A., Stadler, P., Lautenschlaeger, C., Wohlrab, W., Rath, F. W., Molls, M., and Dunst, J. Tumor hypoxia, p53, and prognosis in cervical cancers. Int. J. Radiat. Oncol. Biol. Phys., 50: 865-872, 2001.
12. Loncaster, J. A., Harris, A. L., Davidson, S. E., Logue, J. P., Hunter, R. D., Wycoff, C. C., Pastorek, J., Ratcliffe, P. J., Stratford, I. J., and West, C. M. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res., 61: 6394-6399, 2001.
13. Nordsmark, M., Hoyer, M., Keller, J., Nielsen, O. S., Jensen, O. M., and Overgaard, J. The relationship between tumor oxygenation and cell proliferation in human soft tissue sarcomas. Int. J. Radiat. Oncol. Biol. Phys., 35: 701-708, 1996.
14. Brizel, D. M., Scully, S. P., Harrelson, J. M., Layfield, L. J., Bean, J. M., Prosnitz, L. R., and Dewhirst, M. W. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res., 56: 941-943, 1996.
15. Brizel, D. M., Sibley, G. S., Prosnitz, L. R., Scher, R. L., and Dewhirst, M. W. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int. J. Radiat. Oncol. Biol. Phys., 38: 285-289, 1997.
16. Nordsmark, M., Overgaard, M., and Overgaard, J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother. Oncol., 41: 31-39, 1996.
17. Koukourakis, M. I., Giatromanolaki, A., Sivridis, E., Simopoulos, K., Pastorek, J., Wykoff, C. C., Gatter, K. C., and Harris, A. L. Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin. Cancer Res., 7: 3399-3403, 2001.
18. Hui, E. P., Chan, A. T., Pezzella, F., Turley, H., To, K. F., Poon, T. C., Zee, B., Mo, F., Teo, P. M., Huang, D. P., Gatter, K. C., Johnson, P. J., and Harris, A. L. Coexpression of hypoxia-inducible factors 1α and 2α, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin. Cancer Res., 8: 2595-2604, 2002.
19. Chia, S. K., Wykoff, C. C., Watson, P. H., Han, C., Leek, R. D., Pastorek, J., Gatter, K. C., Ratcliffe, P., and Harris, A. L. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J. Clin. Oncol., 19: 3660-3668, 2001.
20. Swinson, D. E., Jones, J. L., Richardson, D., Wykoff, C., Turley, H., Pastorek, J., Taub, N., Harris, A. L., and O'Byrne, K. J. Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J. Clin. Oncol., 21: 473-482, 2003.
21. Hoskin, P. J., Saunders, M. I., Phillips, H., Cladd, H., Powell, M. E., Goodchild, K., Stratford, M. R., and Rojas, A. Carbogen and nicotinamide in the treatment of bladder cancer with radical radiotherapy. Br. J. Cancer, 76: 260-263, 1997.
22. Kaanders, J. H., Pop, L. A., Marres, H. A., Liefers, J., van den Hoogen, F. J., van Daal, W. A., and van der Kogel, A. J. Accelerated radiotherapy with carbogen and nicotinamide (ARCON) for laryngeal cancer. Radiother. Oncol., 48: 115-122, 1998.
23. Snyder, S. A., Lanzen, J. L., Braun, R. D., Rosner, G., Secomb, T. W., Biaglow, J., Brizel, D. M., and Dewhirst, M. W. Simultaneous administration of glucose and hyperoxic gas achieves greater improvement in tumor oxygenation than hyperoxic gas alone. Int. J. Radiat. Oncol. Biol. Phys., 51: 494-506, 2001.
24. Overgaard, J., and Horsman, M. R. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin. Radiat. Oncol., 6: 10-21, 1996.
25. Levine, E. A. V. S. Blood transfusion in patients receiving radical radiotherapy: a reappraisal. Onkologie, 6: 79-87, 1993.
26. Kelleher, D. K., Matthiensen, U., Thews, O., and Vaupel, P. Tumor oxygenation in anemic rats: effects of erythropoietin treatment versus red blood cell transfusion. Acta Oncol., 34: 379-384, 1995.
27. Lacombe, C. Erythropoietin: from molecular biology to clinical use. Eur. Cytokine Netw., 8: 308-310, 1997.
28. Kelleher, D. K., Mattheinsen, U., Thews, O., and Vaupel, P. Blood flow, oxygenation, and bioenergetic status of tumors after erythropoietin treatment in normal and anemic rats. Cancer Res., 56: 4728-4734, 1996.
29. Thews, O., Kelleher, D. K., and Vaupel, P. Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors. Cancer Res., 61: 1358-1361, 2001.
30. Thews, O., Koenig, R., Kelleher, D. K., Kutzner, J., and Vaupel, P. Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia. Br. J. Cancer, 78: 752-756, 1998.
31. Juul, S. Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain damage. Acta Paediatr. Suppl., 91: 36-42, 2002.
32. Juul, S. E. Nonerythropoietic roles of erythropoietin in the fetus and neonate. Clin. Perinatol., 27: 527-541, 2000.
33. Juul, S. E., Zhao, Y., Dame, J. B., Du, Y., Hutson, A. D., and Christensen, R. D. Origin and fate of erythropoietin in human milk. Pediatr. Res., 48: 660-667, 2000.
34. Acs, G., Acs, P., Beckwith, S. M., Pitts, R. L., Clements, E., Wong, K., and Verma, A. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res., 61: 3561-3565, 2001.
35. Acs, G., Zhang, P. J., Rebbeck, T. R., Acs, P., and Verma, A. Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma. Cancer (Phila.), 95: 969-981, 2002.
36. Campana, W. M., Misasi, R., and O'Brien, J. S. Identification of a neurotrophic sequence in erythropoietin. Int. J. Mol. Med., 1: 235-241, 1998.
37. Campana, W. M., and Myers, R. R. Erythropoietin and erythropoietin receptors in the peripheral nervous system: changes after nerve injury. FASEB J., 15: 1804-1806, 2001.
38. Lanzen, J. L., Braun, R. D., Ong, A. L., and Dewhirst, M. W. Variability in blood flow and pO2 in tumors in response to carbogen breathing. Int. J. Radiat. Oncol. Biol. Phys., 42: 855-859, 1998.
39. Braun, R. D., Lanzen, J. L., Snyder, S. A., and Dewhirst, M. W. Comparison of tumor and normal tissue oxygen tension measurements using OxyLite or microelectrodes in rodents. Am. J. Physiol. Heart Circ. Physiol., 280: H2533-H2544, 2001.
40. Brizel, D. M., Dodge, R. K., Clough, R. W., and Dewhirst, M. W. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother. Oncol., 53: 113-117, 1999.
41. Kelleher, D. K., Thews, O., and Vaupel, P. Can erythropoietin improve tumor oxygenation? Strahlenther Onkol., 174 (Suppl. 4): 20-23, 1998.
42. Vaupel, P., Kallinowski, F., and Okunieff, P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res., 49: 6449-6465, 1989.
43. Ribatti, D., Presta, M., Vacca, A., Ria, R., Giuliani, R., Dell'Era, P., Nico, B., Roncali, L., and Dammacco, F. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood, 93: 2627-2636, 1999.
44. Buchler, P., Reber, H. A., Buchler, M., Shrinkante, S., Buchler, M. W., Friess, H., Semenza, G. L., and Hines, O. J. Hypoxia-inducible factor 1 regulates vascular endothelial growth factor expression in human pancreatic cancer. Pancreas, 26: 56-64, 2003.
45. Semenza, G. L. HIF-1 and mechanisms of hypoxia sensing. Curr. Opin. Cell Biol., 13: 167-171, 2001.
46. Gasparini, G., Toi, M., Miceli, R., Vermeulen, P. B., Dittadi, R., Biganzoli, E., Morabito, A., Fanelli, M., Gatti, C., Suzuki, H., Tominaga, T., Dirix, L. Y., and Gion, M. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy. Cancer J. Sci. Am., 5: 101-111, 1999.
47. Linderholm, B., Tavelin, B., Grankvist, K., and Henriksson, R. Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. J. Clin. Oncol., 16: 3121-3128, 1998.
48. Martinez-Zaguilan, R., Seftor, E. A., Seftor, R. E., Chu, Y. W., Gillies, R. J., and Hendrix, M. J. Acidic pH enhances the invasive behavior of human melanoma cells. Clin. Exp. Metastasis, 14: 176-186, 1996.
49. Reshkin, S. J., Bellizzi, A., Albarani, V., Guerra, L., Tommasino, M., Paradiso, A., and Casavola, V. Phosphoinositide 3-kinase is involved in the tumor-specific activation of human breast cancer cell Na(+)/H(+) exchange, motility, and invasion induced by serum deprivation. J. Biol. Chem., 275: 5361-5369, 2000.
50. Brizel, D. M., Schroeder, T., Scher, R. L., Walenta, S., Clough, R. W., Dewhirst, M. W., and Mueller-Klieser, W. Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys., 51: 349-353, 2001.
51. Walenta, S., Wetterling, M., Lehrke, M., Schwickert, G., Sundfor, K., Rofstad, E. K., and Mueller-Klieser, W. High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res., 60: 916-921, 2000.
52. Kurebayashi, J., Otsuki, T., Moriya, T., and Sonoo, H. Hypoxia reduces hormone responsiveness of human breast cancer cells. Jpn. J. Cancer Res., 92: 1093-1101, 2001.
53. Glaser, C. M., Millesi, W., Kornek, G. V., Lang, S., Schull, B., Watzinger, F., Selzer, E., and Lavey, R. S. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int. J. Radiat. Oncol. Biol. Phys., 50: 705-715, 2001.
54. Littlewood, T. J., Bajetta, E., Nortier, J. W., Vercammen, E., and Rapoport, B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J. Clin. Oncol., 19: 2865-2874, 2001.
55. Teicher, B. A., Lazo, J. S., and Sartorelli, A. C. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res., 41: 73-81, 1981.
56. Teicher, B. A., Holden, S. A., al-Achi, A., and Herman, T. S. Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma. Cancer Res., 50: 3339-3344, 1990.
57. Hall, E. The oxygen effect and reoxygenation. Radiobiology for the Radiologist., Ed. 4, pp. 133-152. Philadelphia: J. B. Lippincott Co., 1994.